Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: A meta-analysis of observational studies

Gynecologic Oncology

Volumn 129, Issue 3, 2013, Pages 613-619

  Lee, Jung Yun ^a   Myung, Seung Kwon ^b,c   Song, Yong Sang ^a  

^a Seoul National University   (South Korea)

^b National Cancer Center   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Cyclooxygenase 2; Epithelial ovarian cancer; Meta analysis; Observational studies; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2;

CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; META ANALYSIS; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE;

CYCLOOXYGENASE 2; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OBSERVATION; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 84877579625     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.02.011     Document Type: Review

References (45)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. W.E. Winter III, G.L. Maxwell, C. Tian, J.W. Carlson, R.F. Ozols, and P.G. Rose Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 3621 3627
3. W.L. Smith, and R. Langenbach Why there are two cyclooxygenase isozymes J Clin Invest 107 2001 1491 1495
4. C. Denkert, M. Kobel, S. Pest, I. Koch, S. Berger, and M. Schwabe Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma Am J Pathol 160 2002 893 903
5. J.S. Lee, Y.D. Choi, J.H. Lee, J.H. Nam, C. Choi, and M.C. Lee Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression Int J Gynecol Cancer 16 Suppl. 1 2006 247 253
6. M. Li, S.Y. Qi, Y. Wang, S.X. Feng, B.Z. Zhang, and R. Wang Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2, and Bcl-2 in borderline ovarian tumors Arch Gynecol Obstet 272 2005 48 52
7. P.K. Singhal, G. Spiegel, D. Driscoll, K. Odunsi, S. Lele, and K.J. Rodabaugh Cyclooxygenase 2 expression in serous tumors of the ovary Int J Gynecol Pathol 24 2005 62 66
8. J.F. Tierney, L.A. Stewart, D. Ghersi, S. Burdett, and M.R. Sydes Practical methods for incorporating summary time-to-event data into meta-analysis Trials 8 2007 16
9. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
10. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
11. J. Lau, J.P. Ioannidis, and C.H. Schmid Quantitative synthesis in systematic reviews Ann Intern Med 127 1997 820 826
12. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
13. J.L. Peters, A.J. Sutton, D.R. Jones, K.R. Abrams, and L. Rushton Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry J Clin Epidemiol 61 2008 991 996
14. G. Ferrandina, L. Lauriola, G.F. Zannoni, A. Fagotti, F. Fanfani, and F. Legge Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients Ann Oncol 13 2002 1205 1211
15. K. Shigemasa, X. Tian, L. Gu, Y. Shiroyama, N. Nagai, and K. Ohama Expression of cyclooxygenase-2 and its relationship to p53 accumulation in ovarian adenocarcinomas Int J Oncol 22 2003 99 105
16. T.L. Erkinheimo, H. Lassus, P. Finne, B.P. van Rees, A. Leminen, and O. Ylikorkala Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma Clin Cancer Res 10 2004 538 545
17. M.R. Raspollini, G. Amunni, A. Villanucci, V. Boddi, G. Baroni, and A. Taddei Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome Gynecol Oncol 92 2004 806 812
18. A. Sakamoto, Y. Yokoyama, M. Umemoto, M. Futagami, T. Sakamoto, and X. Bing Clinical implication of expression of cyclooxygenase-2 and peroxisome proliferator activated-receptor (gamma) in epithelial ovarian tumours Br J Cancer 91 2004 633 638
19. S.S. Seo, Y.S. Song, D.H. Kang, I.A. Park, Y.J. Bang, and S.B. Kang Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer Gynecol Oncol 92 2004 927 935
20. J. Fujimoto, H. Toyoki, H. Sakaguchi, I. Jahan, S.M. Alam, and T. Tamaya Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in ovarian cancer Oncol Rep 15 2006 21 25
21. P. Surowiak, V. Materna, C. Denkert, I. Kaplenko, M. Spaczynski, and M. Dietel Significance of cyclooxygenase 2 and MDR1/P-glycoprotein coexpression in ovarian cancers Cancer Lett 235 2006 272 280
22. K.D. Steffensen, M. Waldstrom, U. Jeppesen, E. Jakobsen, I. Brandslund, and A. Jakobsen The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer Int J Gynecol Cancer 17 2007 798 807
23. P. Athanassiadou, D. Grapsa, P. Athanassiades, M. Gonidi, A.M. Athanassiadou, and A. Tsipis The prognostic significance of COX-2 and survivin expression in ovarian cancer Pathol Res Pract 204 2008 241 249
24. J. Menczer, L. Schreiber, V. Kravtsov, E. Berger, A. Golan, and T. Levy Cox-2 immunohistochemical expression in epithelial ovarian carcinoma and platin sensitivity Eur J Gynaecol Oncol 30 2009 531 535
25. S. Ozuysal, T. Bilgin, T. Ozgur, N. Celik, and T. Evrensel Expression of cyclooxygenase-2 in ovarian serous carcinoma: correlation with angiogenesis, nm23 expression and survival Eur J Gynaecol Oncol 30 2009 640 645
26. R. Ali-Fehmi, A. Semaan, S. Sethi, H. Arabi, S. Bandyopadhyay, and Y.R. Hussein Molecular typing of epithelial ovarian carcinomas using inflammatory markers Cancer 117 2011 301 309
27. A. Ferrero, D. Dompe, N. Ravarino, A. Ramella, L. Fuso, and F. Maggiorotto Angiogenesis and molecular markers in advanced epithelial ovarian cancer: a retrospective study Gynecol Oncol 123 2011 301 307
28. M. Wang, Y. He, L. Shi, and C. Shi Multivariate analysis by Cox proportional hazard model on prognosis of patient with epithelial ovarian cancer Eur J Gynaecol Oncol 32 2011 171 177
29. M. Huang, Q. Chen, J. Xiao, C. Liu, and X. Zhao Prognostic significance of cyclooxygenase-2 in cervical cancer: a meta-analysis Int J Cancer 132 2013 363 373
30. N.B. Jamieson, C.R. Carter, C.J. McKay, and K.A. Oien Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis Clin Cancer Res 17 2011 3316 3331
31. C. Mascaux, B. Martin, M. Paesmans, T. Berghmans, M. Dusart, and A. Haller Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results Br J Cancer 95 2006 139 145
32. S. Li, K. Miner, R. Fannin, J. Carl Barrett, and B.J. Davis Cyclooxygenase-1 and 2 in normal and malignant human ovarian epithelium Gynecol Oncol 92 2004 622 627
33. Y. Matsumoto, O. Ishiko, M. Deguchi, E. Nakagawa, and S. Ogita Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms Int J Mol Med 8 2001 31 36
34. J.T. Casagrande, E.W. Louie, M.C. Pike, S. Roy, R.K. Ross, and B.E. Henderson "Incessant ovulation" and ovarian cancer Lancet 2 1979 170 173
35. M.K. Kim, K. Kim, J.Y. Han, J.M. Lim, and Y.S. Song Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer Genes Nutr 6 2011 109 115
36. M. Shih Ie, and R.J. Kurman Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis Am J Pathol 164 2004 1511 1518
37. P.A. Hall, and D.P. Lane p53 in tumour pathology: can we trust immunohistochemistry? - revisited! J Pathol 172 1994 1 4
38. R. Fujiwaki, K. Iida, H. Kanasaki, T. Ozaki, K. Hata, and K. Miyazaki Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase Hum Pathol 33 2002 213 219
39. Y.E. Joo, J.S. Rew, Y.H. Seo, S.K. Choi, Y.J. Kim, and C.S. Park Cyclooxygenase-2 overexpression correlates with vascular endothelial growth factor expression and tumor angiogenesis in gastric cancer J Clin Gastroenterol 37 2003 28 33
40. B. Singh, and A. Lucci Role of cyclooxygenase-2 in breast cancer J Surg Res 108 2002 173 179
41. C.L. Farrell, J. Megyesi, and R.F. Del Maestro Effect of ibuprofen on tumor growth in the C6 spheroid implantation glioma model J Neurosurg 68 1988 925 930
42. M. Tsujii, S. Kawano, S. Tsuji, H. Sawaoka, M. Hori, and R.N. DuBois Cyclooxygenase regulates angiogenesis induced by colon cancer cells Cell 93 1998 705 716
43. M.A. Murphy, B. Trabert, H.P. Yang, Y. Park, L.A. Brinton, and P. Hartge Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP Diet and Health Study and systematic review Cancer Causes Control 23 2012 1839 1852
44. F. Legge, A. Paglia, M. D'Asta, G. Fuoco, G. Scambia, and G. Ferrandina Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients BMC Cancer 11 2011 214
45. A.K. Reyners, L. de Munck, F.L. Erdkamp, W.M. Smit, K. Hoekman, and R.I. Lalisang A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study Ann Oncol 23 2012 2896 2902